These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
May 2, 2014
Agenus Inc. (Nasdaq: AGEN) today announced that GlaxoSmithKline’s (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, placebocontrolled MAGE-A3ii cancer immunotherapeutic trial in...
Apr 29, 2014
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2014 financial results before the market opens on May 8, 2014. Agenus executives will host a conference...
Apr 28, 2014Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer ImmunotherapiesAgenus is eligible to receive ~$100 million in milestone payments as well as royalties on worldwide product sales
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) announced today that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United...
Apr 16, 2014
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, April 23, 2014....
Mar 26, 2014
Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus’ checkpoint modulator portfolio and immuno-oncology...